Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | CCL5 | P13501 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640269 | 1.00 | CHRM2 (0.35) | CHRM2ALDH1A1MAPK1MGLLCCL5 | |
| SCHEMBL641987 | 0.94 | PAX8 (0.35) | MGLLCCL5CCR5TDP1AKR1C3 | |
| SCHEMBL640693 | 0.94 | PAX8 (0.35) | MGLLCCL5CCR5TDP1AKR1C3 | |
| SCHEMBL641096 | 0.91 | ALDH1A1 (0.40) | CHRM2ALDH1A1MGLLCCL5CCR5 | |
| SCHEMBL641118 | 0.91 | ALDH1A1 (0.40) | CHRM2ALDH1A1MGLLCCL5CCR5 | |
| SCHEMBL641097 | 0.91 | ALDH1A1 (0.40) | CHRM2ALDH1A1MGLLCCL5CCR5 | |
| SCHEMBL640967 | 0.88 | AVPR1B (0.37) | CHRM2ALDH1A1MAPK1MGLLAVPR1B | |
| SCHEMBL641389 | 0.88 | CCR5 (0.35) | MGLLCCL5CCR5 | |
| SCHEMBL10008024 | 0.88 | CCR5 (0.35) | MGLLCCL5CCR5 | |
| SCHEMBL639813 | 0.88 | ALDH1A1 (0.39) | CHRM2ALDH1A1MGLLCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | CHRM2 195/4885ALDH1A1 586/4885MAPK1 2454/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | CHRM2 195/4885ALDH1A1 586/4885MAPK1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.